Effect of Oral EGb761 on Brain Glucose Metabolism in Three Groups of Elderly With Memory Complaint, Mild Alzheimer's Disease, and Cognitively Normal Elderly. Phase II, Randomised, Double-Blind, Parallel Groups, Placebo-Controlled Study.

Trial Profile

Effect of Oral EGb761 on Brain Glucose Metabolism in Three Groups of Elderly With Memory Complaint, Mild Alzheimer's Disease, and Cognitively Normal Elderly. Phase II, Randomised, Double-Blind, Parallel Groups, Placebo-Controlled Study.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2016

At a glance

  • Drugs EGb 761 (Primary)
  • Indications Alzheimer's disease; Memory disorders
  • Focus Therapeutic Use
  • Sponsors Ipsen
  • Most Recent Events

    • 29 Aug 2012 Planned end date changed from 1 Jul 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.
    • 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Apr 2012 Additional lead trial investigator (Helene Mathiex-Fortunet) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top